Stocklytics Platform
PTC Therapeutics
PTCT62
$54.50arrow_drop_up3.27%$1.73
PTCT62

$54.50

arrow_drop_up3.27%
Key Stats
Open$53.50
Prev. Close$52.76
EPS-4.73
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$4.35B
PE Ratio-
LOWHIGH
Day Range52.27
57.04
52 Week Range17.53
57.04
Ratios
P/B Ratio1.74K
Revenue$806.78M
Operating M. %-7.45%
Earnings$0.00
Earnings Growth %42.02%
EBITDA Margin %-8.81%
ROE %-7740.12%
EPS-4.73
no data available for fundamentals

There's no data available for fundamentals

Stock Analysis

Stock Performance

PTCT-
US Tech-
US Market-

PTC Therapeutics (PTCT) Statistics

PTC Therapeutics Inc (PTCT) is a biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapies for rare genetic disorders. As of the latest available data, the company's stock statistics show that PTCT has a market capitalization of $X billion and a current share price of $X. The company's valuation metrics indicate that it has a price-to-earnings ratio of X, a price-to-sales ratio of X, and a price-to-book ratio of X.
When it comes to the fundamental aspects of PTC Therapeutics Inc, the company has shown promising performance. Its revenue per share stands at $X, indicating a strong financial position. Moreover, the company's enterprise to EBITDA ratio, which measures its operating performance, is X, suggesting efficient management and operations. Another positive aspect of PTCT is its profit margin, which stands at X%. This indicates that the company is able to generate substantial profits from its operations.
add PTC Therapeutics to watchlist

Keep an eye on PTC Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has PTC Therapeutics (PTCT) stock's performance compared to its sector and the market over the past year?

Over the past year, PTC Therapeutics (PTCT) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 21.28%, PTC Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 34.40%, it has fallen short of the market average. This comparison highlights PTC Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of PTC Therapeutics (PTCT) stock?

The PE ratio for PTC Therapeutics (PTCT) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of PTC Therapeutics (PTCT) stock?

The Earnings Per Share (EPS) for PTC Therapeutics (PTCT), calculated on a diluted basis, is -$4.73. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of PTC Therapeutics (PTCT) stock?

The operating margin for PTC Therapeutics (PTCT) is -7.45%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of PTC Therapeutics (PTCT) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of PTC Therapeutics (PTCT) is $35.36M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does PTC Therapeutics (PTCT) have?

PTC Therapeutics (PTCT) has a total debt of $2.47B. The net debt, which accounts for cash and cash equivalents against the total debt, is $1.69B.

Take Your Investments to a Whole New Level